Navigation Links
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
Date:7/2/2009

LEUVEN, Belgium and LUND, Sweden, July 3 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402. This follows completion of recruitment of the first cohort of 100 patients ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery. The decision to move ahead with the second cohort of this trial follows unanimous advice from the external efficacy and safety monitoring board to proceed using a higher dose of TB-402.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study is assessing three different doses of TB-402 given as a single intravenous bolus injection post knee replacement surgery, and will enrol a total of 300 patients across 36 centers, mainly in Europe. The objective of the study is to assess the safety and efficacy of the three escalating doses of TB-402.

TB-402 is a recombinant human monoclonal antibody that partially inhibits Factor VIII, a key component of the coagulation cascade. This novel mode of action is expected to reduce the risk of undesirable bleeding events, even at high doses, as well as the need for patient monitoring. These are the two main drawbacks associated with current anticoagulants. In addition, TB-402 is a long-acting agent, which means it could be given as a single dose after surgery to prevent the development of DVT. This would be an attractive option, as all current anticoagulant treatment options require daily treatment for up to several weeks.

Professor Peter Verhamme from the University of Leuven will present additi
'/>"/>

SOURCE ThromboGenics NV and BioInvent International
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. InterMune Announces Start of Phase 1b Trial of ITMN-191
11. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...IEGO, Nov. 6 California American W...s "No Drugs Down the Drain" week for its San Diego...n sponsored by public and private agencies alike t...l pollution in our source water supplies. ,, Ca...rs are encouraged to drop off expired or unwanted ...
(Date:11/5/2009)...TOWN, N.J., Nov. 5 Osteo...ing field of biologic products for regenerative he...ird quarter ended September 30, 2009. ,, "Durin...release of our three new biologic products MagniF...y and Plexur M® Innovative Grafting," said Sa...
(Date:11/5/2009)... RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall/ -..., a specialty pharmaceutical company focused on th... products that address important therapeutic needs...will host a webcast and teleconference with manage...ts on Thursday, November 12, 2009, at 5:00 p.m. Ea...
Breaking Medicine Technology:California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2DNA2 0 Awarded US Patents for Breakthrough Gene Optimization Technology Company 26apos 3Bs Unique Algorithm Enables Expression Yields up to 50 Time 12565 1DNA2 0 Awarded US Patents for Breakthrough Gene Optimization Technology Company 26apos 3Bs Unique Algorithm Enables Expression Yields up to 50 Time 12565 2DNA2 0 Awarded US Patents for Breakthrough Gene Optimization Technology Company 26apos 3Bs Unique Algorithm Enables Expression Yields up to 50 Time 12565 3PhRMA Launches Campaign to Raise Awareness of Success of Medicare Prescription Drug Benefit 48446 1PhRMA Launches Campaign to Raise Awareness of Success of Medicare Prescription Drug Benefit 48446 2Astellas Names Head of Global R 26D Operations 48444 1Astellas Names Head of Global R 26D Operations 48444 2
...udy reports this juice has beneficial e...une 9 CherryPharm -- a proprietary,all-natural ta...enefits of,cherries -- has been shown to improve a...rsity of Rochester Medical Center. This double-bli...fectiveness of CherryPharm,in older adults with in...
...t Benefit Versus Placebo on All Key Eff...NCISCO, June 9 Medivation, Inc.,(Nasdaq: MDVN ) ...s in its,second pivotal Phase 3 trial of the inves...to-moderate Alzheimer,s disease (AD). The internat...efficacy study of oral Dimebon,is known as the CON...
Other Medicine Technology:CherryPharm First All-Natural Food to Improve Sleep 2Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease 2Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease 3Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease 4
(Date:11/7/2009)...ack to stem a growing problem across the U.S. , ...y half of students at four-year colleges do it reg...rinking -- downing five or more alcoholic drinks a...g alcohol as a drug," said Jenny Hwang, associate ...nter at Stony Brook University on Long Island, N.Y...
(Date:11/6/2009)... TSX: COM , VANCOUVER, Nov. 6 /PRNewswire-FirstC...: COM) today announced that it will report financi...0, 2009 on the morning of Monday, November 9, 2009...cast at 9:00am Eastern (6:00am Pacific) on that da...nce call, please dial 416-695-7806 or 888-789-9572...
(Date:11/6/2009).... 6 Centene Corporation (NYSE: CNC ) today annou...re conferences over the next few weeks. ,, Next we...onference, to be held November 11-13, 2009, at the...ne will present Wednesday, November 11th at 4:30 p...parties may access Centene,s presentation at: ht...
(Date:11/6/2009)...Nov. 6 Plan International, a leading children,s d...es around the world, has been asked to deliver eig...ng at the upcoming American Public Health Associat...iladelphia, Pennsylvania on November 7-11, 2009. ...organizations together to address current and emer...
(Date:11/6/2009)...cy, clinic and government programs, expert says , ...ecession has made it more difficult than ever befo...ations, but several options are available, accordi...olis. , First, talk to your pharmacist, advised Ca...professor of pharmacy practice at Butler,s College...
Breaking Medicine News(10 mins):Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3Health News:Centene Corporation to Present at Upcoming Healthcare Conferences 2Health News:Plan's Expertise Highlighted at Premier Health Forum 2Health News: Pay Less for Prescription Drugs 2
...irst heart transplant patient whose donor heart wa... The pioneering operation was performed on the ...uth Wales on 20 February after her body rejected h...attached to it. The operation was performed by...
...gst Italian scientists to show that high cholester... though more studies to prove the same is welcome....on of male hormones that cause prostate cancer, wh...sk of getting afflicted with cancer The resea...
...winner of the prestigious Dada Saheb Phalke Award,...is afternoon. //The superstar had come in the lime...smuggler Veerappan for more than 100 days, about s...ysician Dr Ramana Rao said. Dr Bhujanga Shetty of ...
...ods it ahs been found that survival rates followin... three-fold when emergency medical// personnel use... Arizona Sarver Heart Center. Cardiocerebral Res...ael J. Kellum, MD, leading author of the study rep...
...in 2000 and was later recommendation for all child... in the rates of pneumonia among young infants. /...ease among children younger than 2 years of age wa...tion rate. But in the present study that was condu...
...ases are an urban lifestyle phenomenon, a three-ye... revealed that heart-related problems// are the la...ive leading institutes led by the Byrraju Foundati...se Control (CCDC), the CARE Foundation in India, t...
Other Medicine News:Health News:Donor Heart Gives Way for Patient’s Own Hear 2Health News:Paramedics save more lives following unconventional rules 2Health News:Mortality Rates Due To Heart Diseases Is High In Rural Areas Too 2
...ings where a more secure band is desired for adult...ve wristband is appropriate. The design allows for... be placed on the wrist and the second to be held ...This is particularly useful in a hospital situatio...
IDENTI-PRINT II
IDENTI-MATCH II
Digital High Mag
Medicine Products: